Tandem Diabetes Care (TNDM) Enterprise Value Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.12% |
| Dec 31, 2025 | 9.61% |
| Sep 30, 2025 | 7.23% |
| Jun 30, 2025 | 5.85% |
| Mar 31, 2025 | -18.14% |
| Dec 31, 2024 | -19.96% |
| Sep 30, 2024 | -24.70% |
| Jun 30, 2024 | -28.05% |
| Mar 31, 2024 | -30.08% |
| Dec 31, 2023 | -29.39% |
| Sep 30, 2023 | -20.65% |
| Jun 30, 2023 | -42.44% |
| Mar 31, 2023 | -48.53% |
| Dec 31, 2022 | -112.67% |
| Sep 30, 2022 | -103.49% |
| Jun 30, 2022 | -86.99% |
| Mar 31, 2022 | -79.02% |
| Dec 31, 2021 | -124.83% |
| Sep 30, 2021 | -77.18% |
| Jun 30, 2021 | -58.61% |
| Mar 31, 2021 | -49.64% |
| Dec 31, 2020 | -46.81% |
| Sep 30, 2020 | -41.55% |
| Jun 30, 2020 | -34.25% |
| Mar 31, 2020 | -6.60% |
| Dec 31, 2019 | -21.27% |
| Sep 30, 2019 | -14.46% |
| Jun 30, 2019 | -6.86% |
| Mar 31, 2019 | -2.54% |
| Dec 31, 2018 | 0.07% |
| Sep 30, 2018 | -65.80% |
| Jun 30, 2018 | -23.48% |
| Mar 31, 2018 | -19.55% |